New drug aims to stop dangerous transplant complication
NCT ID NCT03605927
Summary
This study tested if adding a new drug called BMS-986004 to standard anti-rejection medicine could safely prevent a serious complication called acute Graft-Versus-Host Disease (GVHD). It involved 45 patients with blood cancers who received a stem cell transplant from a donor. The main goal was to see if this combination could reduce the risk of severe GVHD in the first 100 days after transplant.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GRAFT -VERSUS-HOST-DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Cancer Center
Duarte, California, 91010, United States
-
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612, United States
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
Conditions
Explore the condition pages connected to this study.